A novel serum m 7 G-harboring microRNA signature for cancer detection

• Published in: Frontiers in genetics Vol. 15; p. 1270302
• Main Authors: Chen, Yaxin, Xie, Yufang, Bi, Liyun, Ci, Hang, Li, Weimin, Liu, Dan
• Format: Journal Article
• Language: English
• Published: Switzerland 2024
• Subjects: pan-cancer; cancer diagnosis; microRNA; m7G; liquid biopsy
• ISSN: 1664-8021; 1664-8021

Emerging evidence points to the exceptional importance and value of m G alteration in the diagnosis and prognosis of cancers. Nonetheless, a biomarker for precise screening of various cancer types has not yet been developed based on serum m G-harboring miRNAs. A total of 20,702 serum samples, covering 12 cancer types and consisting of 7,768 cancer samples and 12,934 cancer-free samples were used in this study. A m G target miRNA diagnostic signature (m G-miRDS) was established through the least absolute shrinkage and selection operator (LASSO) analyses in a training dataset ( = 10,351), and validated in a validation dataset ( = 10,351). The m G-miRDS model, a 12 m G-target-miRNAs signature, demonstrated high accuracy and was qualified for cancer detection. In the training and validation cohort, the area under the curve (AUC) reached 0.974 (95% CI 0.971-0.977) and 0.972 (95% CI 0.969-0.975), respectively. The m G-miRDS showed superior sensitivity in each cancer type and had a satisfactory AUC in identifying bladder cancer, lung cancer and esophageal cancer. Additionally, the diagnostic performance of m G-miRDS was not interfered by the gender, age and benign disease. Our results greatly extended the value of serum circulating miRNAs and m G in cancer detection, and provided a new direction and strategy for the development of novel biomarkers with high accuracy, low cost and less invasiveness for mass cancer screening, such as ncRNA modification.